DiaMedica Advances Clinical Pipeline and Reaches Key Stroke Trial Threshold

DiaMedica Therapeutics Inc. reported progress across its clinical trial pipeline during its third-quarter 2026 financial update, highlighted by reaching a key enrollment target in its pivotal acute ischemic stroke study. The company enrolled its 200th participant in the Phase 2/3 ReMEDy2 trial in October, triggering a planned interim efficacy readout set for the first quarter of 2027.

The biopharmaceutical firm is evaluating its lead candidate DM199, a recombinant form of human tissue kallikrein-1 engineered to improve vascular function and blood flow via the bradykinin-2 receptor pathway. In addition to stroke, the treatment is targeted at pregnancy-related conditions. DiaMedica finished enrolling 12 participants across two dose cohorts in a Phase 2 study for early-onset fetal growth restriction conducted at Tygerberg Hospital in South Africa, with preliminary data anticipated in late November.

To support global expansion of its Phase 2 preeclampsia program, DiaMedica received regulatory authorizations from Health Canada and the European Medicines Agency. The company is currently generating additional rat toxicology data to fulfill requirements for an investigational new drug application with the U.S. Food and Drug Administration.

What to watch next: Market participants will focus on the preliminary Phase 2 fetal growth restriction trial data expected in late November, followed by the ReMEDy2 interim efficacy analysis in early 2027.